Valuation: Eagle Pharmaceuticals, Inc.

Market Cap 67.92M 58.66M 55.2M 50.17M 94.35M 6.51B 95.74M 647M 254M 3.25B 255M 249M 10.84B P/E 2021
-77x
P/E 2022 10.7x
Enterprise Value 78.11M 67.46M 63.47M 57.69M 109M 7.48B 110M 745M 292M 3.74B 293M 287M 12.47B EV / Sales 2021
3.44x
EV / Sales 2022 1.23x
Free-Float
74.04%
Yield 2021 *
-
Yield 2022 -
1 day+465.59%
1 week+465.59%
Current month+60.81%
3 months+58.58%
6 months+138.00%
Current year-15.00%
1 month 0.05
Extreme 0.0504
0.6
Current year 0
Extreme 0.0011
0.85
1 year 0
Extreme 0.0011
3.72
3 years 0
Extreme 0.0011
18.31
5 years 0
Extreme 0.0011
58.25
10 years 0
Extreme 0.0011
97.15
Manager TitleAgeSince
Chief Executive Officer 63 2023-11-26
Director of Finance/CFO 52 2024-11-10
Corporate Officer/Principal - 2022-07-17
Director TitleAgeSince
Director/Board Member 83 2007-02-28
Chairman 63 2016-06-28
Director/Board Member 65 2016-06-30
Date Insider Type Main position Quantity % Market Cap.
2/28/24 Tax 2,119 0.0163%
2/27/24 Free 16,104 0.1240%
2/27/24 Free

Chief Financial Officer

5,389 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
+465.59%+465.59%-81.41%-96.59% 7.75M
+10.90%+12.17%+75.56%+35.99% 333B
+1.57%-0.46%+25.60%-11.78% 68.84B
+1.89%+4.41%+51.87%+149.37% 11.9B
+0.99%+1.05%-1.61%+0.90% 8.41B
+0.12%-5.75%-14.01%-1.39% 4.72B
0.00%-7.01%-29.99%+14.02% 4.2B
-8.17%-24.88%-25.84%+13.46% 3.48B
+0.36%+1.82%+16.05%+55.27% 2.85B
-2.79%-6.85%-9.11%-6.03% 2.19B
Average +47.02%-2.93%+0.71%+15.32% 44.01B
Weighted average by Cap. +8.48%+2.19%+62.05%+30.04%

Financials

2021 2022
Net sales 172M 148M 139M 127M 238M 16.44B 242M 1.64B 641M 8.22B 644M 630M 27.38B 317M 273M 257M 234M 440M 30.34B 446M 3.02B 1.18B 15.17B 1.19B 1.16B 50.54B
Net income -8.63M -7.45M -7.01M -6.37M -11.98M -827M -12.16M -82.24M -32.23M -413M -32.39M -31.69M -1.38B 35.64M 30.78M 28.96M 26.32M 49.51M 3.41B 50.24M 340M 133M 1.71B 134M 131M 5.69B
Net Debt -67.84M -58.59M -55.13M -50.1M -94.24M -6.5B -95.62M -647M -253M -3.25B -255M -249M -10.83B 10.19M 8.8M 8.28M 7.52M 14.15M 976M 14.36M 97.11M 38.06M 488M 38.25M 37.42M 1.63B
Logo Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial specializations. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO through its wholly owned subsidiary Acacia Pharma Inc. The Company’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Its pipeline includes ENA-001 and EA-114. EA-114 is a novel and proprietary formulation of fulvestrant being developed for hormone-receptor-positive (HR+) metastatic breast cancer. ENA-001 is an investigational new chemical entity being developed by the Company’s partner, Enalare, as an agnostic respiratory stimulant for multiple patient populations experiencing respiratory depression.
Employees
134
Date Price Change Volume
26-08-12 US$0.5950 +465.59% 2,217
26-08-11 US$0.1052 +52.80% 4,982
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. EGRX Stock